A Phase 1, Open-label Study of the Absolute Bioavailability of [14C]-LY4064809 in Healthy Adult Participants
Eli Lilly and Company
Summary
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Must be healthy as shown by medical history, physical examination, laboratory tests and heart monitoring * Must have normal blood pressure and pulse rate * Must have a history of a minimum of 1 bowel movement per day * Must have body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m2) * Must be healthy men or healthy women who are not of childbearing potential * Healthy men with partners who can become pregnant must remain abstinent or use contraceptives consistent with local regulations Exclusion Criteria: * Must not have a significant history or pre…
Interventions
- DrugLY4064809
Administered orally
- Drug[14C]-LY4064809
Administered by IV infusion
Location
- Fortrea Clinical Research Unit Inc. - MadisonMadison, Wisconsin